Thank you.
Mr. Chairman, what we are looking for is basically a $1.42 billion re-profile.
This is mostly focused on the COVID component, which is medical research and vaccine development, and which is again one of those core pieces where we are continuing to receive more bivalent vaccines. There are also logistics for vaccine distribution as we move the vaccines when we receive them from the manufacturers to the PTs.
Also, there is a component of the national emergency strategic stockpile in there.
Finally, there is some amount of testing, which is related to both waste-water surveillance and other testing that the National Microbiology Laboratory continues to do as such.